These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10424840)

  • 1. Power and sample size in cost-effectiveness analysis.
    Laska EM; Meisner M; Siegel C
    Med Decis Making; 1999; 19(3):339-43. PubMed ID: 10424840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ratio-based and net benefit-based approaches to health care resource allocation: proofs of optimality and equivalence.
    Laska EM; Meisner M; Siegel C; Stinnett AA
    Health Econ; 1999 Mar; 8(2):171-4. PubMed ID: 10342730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The usefulness of average cost-effective ratios.
    Laska EM; Meisner M; Siegel C
    Health Econ; 1997; 6(5):497-504. PubMed ID: 9353650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale.
    Elbasha EH; Messonnier ML
    Health Econ; 2004 Jan; 13(1):21-35. PubMed ID: 14724891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.
    Gafni A; Birch S
    Soc Sci Med; 2006 May; 62(9):2091-100. PubMed ID: 16325975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Building uncertainty into cost-effectiveness rankings: portfolio risk-return tradeoffs and implications for decision rules.
    O'Brien BJ; Sculpher MJ
    Med Care; 2000 May; 38(5):460-8. PubMed ID: 10800973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Portfolio theory and cost-effectiveness analysis: a further discussion.
    Sendi P; Al MJ; Rutten FF
    Value Health; 2004; 7(5):595-601. PubMed ID: 15367254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty.
    Sendi P; Al MJ
    Soc Sci Med; 2003 Sep; 57(6):969-74. PubMed ID: 12878098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources.
    Sendi P; Al MJ; Gafni A; Birch S
    Soc Sci Med; 2003 Dec; 57(11):2207-15. PubMed ID: 14512250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinky thresholds revisited: opportunity costs differ in the NE and SW quadrants.
    Eckermann S
    Appl Health Econ Health Policy; 2015 Feb; 13(1):7-13. PubMed ID: 25362257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incremental cost effectiveness evaluation in clinical research.
    Krummenauer F; Landwehr I
    Eur J Med Res; 2005 Jan; 10(1):18-22. PubMed ID: 15737949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An opportunity cost approach to sample size calculation in cost-effectiveness analysis.
    Gafni A; Walter SD; Birch S; Sendi P
    Health Econ; 2008 Jan; 17(1):99-107. PubMed ID: 17497751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonparametric statistical methods for cost-effectiveness analyses.
    Dinh P; Zhou XH
    Biometrics; 2006 Jun; 62(2):576-88. PubMed ID: 16918923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Portfolio theory and the alternative decision rule of cost-effectiveness analysis: theoretical and practical considerations.
    Sendi P; Al MJ; Gafni A; Birch S
    Soc Sci Med; 2004 May; 58(10):1853-5. PubMed ID: 15020003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of cost-effectiveness analysis to multiple products: a practical guide.
    Bala MV; Zarkin GA
    Am J Manag Care; 2002 Mar; 8(3):211-8. PubMed ID: 11915971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the estimation of cost-effectiveness ratios.
    Johannesson M
    Health Policy; 1995 Mar; 31(3):225-9. PubMed ID: 10142618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
    Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
    Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunity costs and uncertainty in the economic evaluation of health care interventions.
    Sendi P; Gafni A; Birch S
    Health Econ; 2002 Jan; 11(1):23-31. PubMed ID: 11788979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision Making for Healthcare Resource Allocation: Joint v. Separate Decisions on Interacting Interventions.
    Dakin H; Gray A
    Med Decis Making; 2018 May; 38(4):476-486. PubMed ID: 29683792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.